A new collaboration co-funded with €8.5m from the European Commission has been launched to accelerate the development of new vaccines, drugs and microbicides to fight against many poverty related diseases such as tuberculosis (TB), HIV, malaria, hepatitis B and hepatitis C.
Co-ordinated by the Medicines and Healthcare products Regulatory Agency’s (MHRA) National Institute for Biological Standards and Control (NIBSC), the collaborative infrastructure programme, ‘European Research Infrastructures for Poverty Related Diseases’ (EURIPRED), aims to strengthen the knowledge infrastructure across diseases.
Researchers and scientists from 17 research partners in ten countries will collaborate in the new EURIPRED programme.
Despite substantial efforts to reduce the burden of poverty related diseases, HIV/AIDS, TB and malaria still account for 3.4 million deaths globally every year.
Underdiagnosis and tough treatment courses are two of the reasons for the continued prevalence, according to NIBSC.
NIBSC scientific lead at the Centre for AIDS Reagents and coordinator of EURIPRED Meghna Ramaswamy said: "By creating partnerships between European scientists and international research teams from disease endemic countries, we expect to speed-up the development of new vaccines, drugs and microbicides.
"By minimising fragmentation and duplication of research efforts and pooling resources, EURIPRED can improve research efficiency and effectiveness."
EURIPRED includes a team of European scientists, institutes and networks in the field of poverty related diseases. The aim is to speed-up the development of new vaccines, drugs and microbicides by pooling resources, reducing duplication of research efforts thereby improving research efficiency and effectiveness.
Other objectives of the project, which will be reinforced by partners in China, Russia and Kenya, will include collaboration on the selection, development, production, and validation of reference reagents, assays, and standards and training.